Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 14 | 2025 | 477 | 2.200 |
Why?
|
| Brain Neoplasms | 17 | 2025 | 1218 | 1.820 |
Why?
|
| Brain Stem Neoplasms | 7 | 2023 | 40 | 1.620 |
Why?
|
| Medulloblastoma | 8 | 2021 | 380 | 0.750 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 192 | 0.740 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 1754 | 0.680 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 572 | 0.670 |
Why?
|
| Chemoradiotherapy | 6 | 2025 | 117 | 0.610 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2023 | 931 | 0.600 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2014 | 26 | 0.550 |
Why?
|
| Cerebellar Neoplasms | 5 | 2021 | 314 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 1308 | 0.490 |
Why?
|
| Ependymoma | 3 | 2025 | 138 | 0.450 |
Why?
|
| Antigens, CD | 2 | 2014 | 416 | 0.450 |
Why?
|
| Glycoproteins | 2 | 2014 | 334 | 0.450 |
Why?
|
| Pyrimidines | 3 | 2023 | 405 | 0.410 |
Why?
|
| Glioblastoma | 3 | 2023 | 330 | 0.400 |
Why?
|
| Optic Nerve Glioma | 2 | 2025 | 21 | 0.400 |
Why?
|
| Peptides | 2 | 2014 | 828 | 0.400 |
Why?
|
| Benzimidazoles | 4 | 2025 | 142 | 0.390 |
Why?
|
| Down-Regulation | 1 | 2014 | 651 | 0.380 |
Why?
|
| Oncolytic Viruses | 3 | 2023 | 75 | 0.370 |
Why?
|
| Proton Therapy | 2 | 2025 | 150 | 0.360 |
Why?
|
| Oncolytic Virotherapy | 3 | 2023 | 89 | 0.360 |
Why?
|
| Child | 32 | 2025 | 25112 | 0.360 |
Why?
|
| AC133 Antigen | 3 | 2024 | 35 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 329 | 0.340 |
Why?
|
| Mice, SCID | 12 | 2023 | 565 | 0.330 |
Why?
|
| Wilms Tumor | 2 | 2019 | 116 | 0.310 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 50 | 0.290 |
Why?
|
| Neuroimaging | 2 | 2020 | 352 | 0.260 |
Why?
|
| Neoplasm Grading | 6 | 2025 | 257 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2023 | 4433 | 0.250 |
Why?
|
| Child, Preschool | 16 | 2025 | 14375 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 637 | 0.220 |
Why?
|
| Piperazines | 2 | 2021 | 251 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2025 | 63 | 0.220 |
Why?
|
| CD57 Antigens | 1 | 2024 | 5 | 0.220 |
Why?
|
| Astrocytoma | 1 | 2025 | 96 | 0.220 |
Why?
|
| Humans | 42 | 2025 | 126129 | 0.220 |
Why?
|
| Fireflies | 1 | 2023 | 1 | 0.210 |
Why?
|
| Visual Acuity | 2 | 2025 | 644 | 0.210 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 18 | 0.210 |
Why?
|
| Gangliosides | 1 | 2024 | 66 | 0.210 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 3474 | 0.200 |
Why?
|
| Sexual Harassment | 1 | 2023 | 19 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 786 | 0.190 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 47 | 0.190 |
Why?
|
| Mice | 14 | 2024 | 17616 | 0.190 |
Why?
|
| Animals | 20 | 2024 | 33226 | 0.190 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1574 | 0.190 |
Why?
|
| Neutropenia | 1 | 2023 | 199 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 72 | 0.190 |
Why?
|
| Aurora Kinase A | 2 | 2023 | 35 | 0.190 |
Why?
|
| Azepines | 2 | 2023 | 61 | 0.180 |
Why?
|
| Adolescent | 16 | 2025 | 19986 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 223 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 65 | 0.180 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 360 | 0.170 |
Why?
|
| Craniospinal Irradiation | 1 | 2021 | 50 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 108 | 0.170 |
Why?
|
| Mice, Inbred NOD | 4 | 2023 | 287 | 0.170 |
Why?
|
| Thalidomide | 1 | 2020 | 35 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2014 | 250 | 0.170 |
Why?
|
| Male | 24 | 2025 | 62225 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2020 | 53 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1942 | 0.160 |
Why?
|
| Prognosis | 6 | 2025 | 4697 | 0.150 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 48 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 269 | 0.150 |
Why?
|
| Pyridines | 1 | 2021 | 248 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5107 | 0.150 |
Why?
|
| Female | 23 | 2025 | 68037 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 423 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1233 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 566 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2018 | 27 | 0.150 |
Why?
|
| Digoxin | 1 | 2018 | 38 | 0.150 |
Why?
|
| Systems Biology | 1 | 2018 | 60 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 223 | 0.140 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 135 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 18 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3593 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2020 | 1475 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 346 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1783 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2025 | 203 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 260 | 0.130 |
Why?
|
| Germinoma | 1 | 2016 | 30 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 63 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 222 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 722 | 0.120 |
Why?
|
| Disease Progression | 4 | 2025 | 2110 | 0.120 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1097 | 0.110 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 137 | 0.110 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 23 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 34 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 872 | 0.110 |
Why?
|
| Young Adult | 7 | 2024 | 9635 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 161 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2014 | 46 | 0.100 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 36 | 0.100 |
Why?
|
| Picornaviridae | 1 | 2013 | 19 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2014 | 707 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2017 | 677 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 123 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2014 | 298 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 656 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 354 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 196 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 12803 | 0.080 |
Why?
|
| Thiourea | 1 | 2010 | 10 | 0.080 |
Why?
|
| Survival Rate | 3 | 2025 | 2055 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 155 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 293 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 232 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2010 | 481 | 0.070 |
Why?
|
| Apoptosis | 4 | 2018 | 1803 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1220 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 277 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1239 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 16831 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1408 | 0.070 |
Why?
|
| Kinetics | 1 | 2009 | 1092 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2391 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1375 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 994 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.050 |
Why?
|
| Cell Movement | 2 | 2021 | 846 | 0.050 |
Why?
|
| Pons | 1 | 2023 | 33 | 0.050 |
Why?
|
| Mutation | 3 | 2023 | 5933 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1604 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 108 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 300 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 237 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 64 | 0.040 |
Why?
|
| Morpholines | 1 | 2021 | 65 | 0.040 |
Why?
|
| Dissection | 1 | 2021 | 58 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 150 | 0.040 |
Why?
|
| Brain | 3 | 2021 | 3031 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2012 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 119 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 98 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2020 | 48 | 0.040 |
Why?
|
| Everolimus | 1 | 2021 | 48 | 0.040 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 10 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 135 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 770 | 0.040 |
Why?
|
| Purines | 1 | 2021 | 111 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 48 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 62 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 56 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 76 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 270 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1221 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2021 | 155 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 75 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 114 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2019 | 72 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 174 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 230 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 161 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 30314 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 61 | 0.040 |
Why?
|
| Allopurinol | 1 | 2019 | 77 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 38 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 1236 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 110 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 609 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2019 | 64 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 226 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 273 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 450 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 36 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 712 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 857 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 527 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 331 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1293 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1598 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 99 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 259 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 209 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2752 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 1036 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 758 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2552 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 189 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1107 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12393 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2176 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2766 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 537 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 145 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 23 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 685 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 722 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1639 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 216 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3895 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 821 | 0.020 |
Why?
|
| Primary Cell Culture | 1 | 2012 | 103 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1577 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 243 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6030 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1739 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 523 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1011 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3149 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1019 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2906 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 72 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 287 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6178 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4472 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4516 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1901 | 0.010 |
Why?
|